BIT
NTLA icon

BlackRock Institutional Trust’s Intellia Therapeutics NTLA Stock Holding History

BlackRock Institutional Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.68M Buy
128,308
+3,823
+3% +$57.4K ﹤0.01% 3122
2016
Q3 		$2.12M Buy
124,485
+66,572
+115% +$1.29M ﹤0.01% 3025
2016
Q2 		$1.24M Buy
+57,913
New +$1.54M ﹤0.01% 3237

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock Institutional Trust's NTLA Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Intellia Therapeutics (NTLA) stake by 3.1% in Q4 2016, buying an estimated $57.4K and bringing the position to 128,308 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

BlackRock Institutional Trust first reported a position in NTLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $2.12M in Q3 2016. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • BlackRock Institutional Trust held 128,308 shares of Intellia Therapeutics worth $1.68M as of Q4 2016.
  • BlackRock Institutional Trust bought 3,823 Intellia Therapeutics shares in Q4 2016, an estimated $57.4K.
  • Intellia Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3122 holding.
  • BlackRock Institutional Trust first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Institutional Trust's Intellia Therapeutics position peaked at $2.12M in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.